#Autolus
Acute Lymphocytic Leukemia Pipeline Update 2026: Clinical Development Status, Collaborations, and Key Companies to Watch | Cellectis S.A, Autolus Limited, Takara Bio, AbbVies, Janssen, Jazz Pharma
https://www.pressreleasecc.com/2026/11/05/acute-lymphocytic-leukemia-pipeline-update-2026-clinical-development-status-collaborations-and-key-companies-to-watch-cellectis-s-a-autolus-limited-takara-bio-abbvies-janssen-jazz-pharma
www.pressreleasecc.com
November 18, 2026 at 7:12 PM
Autolus GmbH filed a 10-Q with the SEC on 10 Nov 2026 covering the period ending 30 Sep 2026: revenue $41.2 million and R&D spend $30.9 million.

R&D is 74.9% of revenue for the period ending 30 Sep 2026.

What should Autolus publish next: indication, endpoints, or timeline?
Autolus: $41.2M revenue, $30.9M R&D, quarter to Sep 2026
Autolus GmbH filed a 10-Q with the SEC on 10 Nov 2026 covering the period ending 30 Sep 2026: revenue $41.2 million and R&D spend $30.9 million. R&D is 74.9% of revenue for the period ending 30 Sep 2026. Source: US SEC (EDGAR).
enclai.net
November 12, 2026 at 2:25 PM
Autolus Therapeutics ($AUTL) – 13D holder update

• Holder: Blackstone
• Stake: now 7.6% (about $27M)
• Filed: Nov 10 · Schedule 13D/A

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#ActivistInvesting #Stocks #Investing #ElixStocks
Blackstone Inc.: 7.6% of Autolus Therapeutics ($AUTL)
Schedule 13D/A filed Nov 10. Who filed, the stake, and how it changed.
elixstocks.com
November 11, 2026 at 9:16 PM
The firm also presented data for Aucatzyl in lupus today; CEO Christian Itin said he's not concerned about safety issues seen in other autoimmune CAR T trials.
Autolus Delays First Look at Aucatzyl Multiple Sclerosis Data as Revenue Exceeds Expectations
Autolus Delays First Look at Aucatzyl Multiple Sclerosis Data as Revenue Exceeds Expectations
ebx.sh
November 11, 2026 at 12:48 AM
#AUTL Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergenc…

https://www.stocktitan.net/news/AUTL/autolus-therapeutics-presents-longer-term-follow-up-data-from-i1gh1ddbn98o.html?utm_source=stocktitan-bluesky&utm_medium=social
Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Autolus Therapeutics (Nasdaq: AUTL) presented longer-term Phase I CARLYSLE results for obe-cel in patients with severe, treatment-resistant systemic lupus erythematosus.At the August 11, 2026 cutoff, 15 patients had received obe-cel, with adult follow-up extending to 25.5 months. Disease activity scores improved, and DORIS remission criteria were achieved by most participants, including 100% followed for at least six months. Among participants followed for at least six months, complete renal response occurred in 6/9 (66.7%) at any time after infusion; one participant (11.1%) achieved partial renal response, beginning at Month 7. No severe renal flares were observed.No ICANS neurological toxicity, HLH/IEC-HS inflammatory syndromes or Grade ≥3 cytokine release syndrome occurred. Obe-cel is also being evaluated in the Phase II LUMINA trial for severe, treatment-resistant lupus with active lupus nephritis, using a single 50M dose.
www.stocktitan.net
November 10, 2026 at 9:05 PM
#$AUTL weekly close $1.52 (-1.3% w/w), below SMA50 $1.91 / below SMA200 $1.67, RSI 36.6. Support $1.48, resistance $1.87. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/autolus-ther...
October 30, 2026 at 9:33 PM
#$AUTL weekly close $1.52 (-1.3% w/w), below SMA50 $1.91 / below SMA200 $1.67, RSI 36.6. Support $1.48, resistance $1.87. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/autolus-ther...
October 30, 2026 at 9:33 PM
$AUTL — Q3 results on 10 Nov.

Information only — not investment advice.

https://www.merlintrader.com/autolus-therapeutics-stock-hub/
October 27, 2026 at 8:29 PM
#$AUTL daily chart
Friday -7.0% to $1.60 on 2.35M shares.
Lupus follow-up at ACR; ALARIC data by year-end.
Support $1.17 / resistance $1.68.
Hub: www.merlintrader.com/autolus-ther...
October 18, 2026 at 7:53 PM
AUTL Q2 2026 earnings: Revenue $46M (+118.4%) · EPS $-0.15. Autolus doubled AUCATZYL sales to $45.7M (+118%) and turned gross margin positive at ~55%, narrowing its net loss to $39.1M; a raised $140–150M 2026 guide and a $75M Perceptive lo…
https://financialreportinsights.com/companies/autl/2026/q2
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings: Revenue $46M (+118.4%)
Autolus doubled AUCATZYL sales to $45.7M (+118%) and turned gross margin positive at ~55%, narrowing its net loss to $39.1M; a raised $140–150M 2026 guide and a $75M Perceptive loan stretch cash into Q2 2028.
financialreportinsights.com
October 8, 2026 at 11:10 PM
October 5: longer CARLYSLE follow-up of obe-cel in severe, refractory lupus comes as an ACR Convergence poster on November 10.
Autolus (#$AUTL): Can AUCATZYL Sustain Its Commercial Momentum?
www.merlintrader.com/autolus-ther...
Autolus ($AUTL): AUCATZYL And The Next Clinical Tests
Autolus ($AUTL): AUCATZYL sales, margins, cash, financing warrants and the next lupus and amyloidosis data, with dated primary sources.
www.merlintrader.com
October 6, 2026 at 8:32 AM
Autolus (#$AUTL): RMAT Designation for Obe-cel in Lupus, ACR Data in November

Free Biotech Catalyst Calendar on Merlintrader.

www.merlintrader.com/autolus-ther...
September 23, 2026 at 9:43 PM
Autolus Secures FDA RMAT Status for Obe-Cel in Lupus Treatment

Autolus Therapeutics secured Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration f…

Read more: https://embers.news/article/autolus-secures-fda-rmat-status-for-obe-cel-in-lupus-treatment-60452
Autolus Secures FDA RMAT Status for Obe-Cel in Lupus Treatment
Autolus Therapeutics secured Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration for its lead CAR T cell therapy candidate, obe-cel, targeting systemic lupus erythematosus and lupus nephritis as clinical trials advance.
embers.news
September 17, 2026 at 6:04 PM